Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
08/2003
08/28/2003CA2471421A1 Rna interference mediated inhibition of protein typrosine phosphatase-1b (ptp-1b) gene expression using short interfering nucleic acid (sina)
08/28/2003CA2468631A1 Prostaglandin composition for the treatment of erectile dysfunction
08/28/2003CA2459532A1 Rna interference by modified short interfering nucleic acid
08/28/2003CA2456444A1 Rna interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (sina)
08/28/2003CA2455506A1 Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
08/28/2003CA2440190A1 Levothyroxine compositions and methods
08/27/2003EP1338638A1 Aggregate-forming agent
08/27/2003EP1338288A1 Cellulosic particle for pharmaceutical preparation
08/27/2003EP1338271A1 Aqeous solution of ascorbic acid
08/27/2003EP1337664A2 Method for introducing antisense oligonucleotides into eucaryotic cells
08/27/2003EP1337630A2 Modified arginine deiminase
08/27/2003EP1337539A2 Linkable sialyl lewis x analogs
08/27/2003EP1337504A2 Novel polyamine analog-amino acid conjugates useful as anticancer agents
08/27/2003EP1337285A1 Implants with a phosphazene-containing coating
08/27/2003EP1337276A2 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
08/27/2003EP1337274A2 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers
08/27/2003EP1337273A2 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
08/27/2003EP1337270A2 Long-acting cytokine derivatives and pharmaceutical compositions comprising them
08/27/2003EP1337266A1 Mineralized collagen-polysaccharide matrix for bone and cartilage repair
08/27/2003EP1337262A2 Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
08/27/2003EP1337260A1 Preparation for strengthening the immune response in the waldeyer's ring and the oronasal mucosa by intranasal administration
08/27/2003EP1337249A1 Compositions and methods for administration of pharmacologically active compounds
08/27/2003EP1337248A1 Methods for treatment of inflammatory diseases
08/27/2003EP1337243A2 Delayed-release pharmaceutical formulations containing proinsulin c-peptide
08/27/2003EP1337242A2 Gene delivery formulations and methods for treatment of ischemic conditions
08/27/2003EP1337237A2 Pharmaceutical preparations comprising corticosteroids and antiinfective agents
08/27/2003EP1337233A1 Use of at least a sulphonic amino derivative in a composition promoting skin peeling
08/27/2003EP1337226A1 Cosmetic or dermatological agent in the form of a creamy permanent mousse or a stable foamed cream
08/27/2003EP1337225A1 Fine-grained emulsions
08/27/2003EP1337217A1 Methods and apparatus for making seamless capsules
08/27/2003EP1267834A4 Cationic liposomes
08/27/2003EP1259244B1 Veterinary compositions for the treatment of parasitic diseases
08/27/2003EP1189690B1 Method for production of microcapsules
08/27/2003EP1183047B1 Pharmaceutical preparation
08/27/2003EP1169046B1 Pulmonary delivery of protonated/acidified nucleic acids
08/27/2003EP1161228B1 Composition comprising isoquercetin and ascorbic acid in a sustained release form
08/27/2003EP1157030B1 Echinocandin/carbohydrate complexes
08/27/2003EP1143920B1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system
08/27/2003EP1115384B1 Fentanyl composition for the treatment of acute pain
08/27/2003EP1109806B1 Complexes of paroxetine, with cyclodextrins or cyclodextrin derivates
08/27/2003EP1061951B1 Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin
08/27/2003EP1033972B1 Drug delivery system with two-step targeting
08/27/2003EP1030697B1 Biodegradable polymer scaffold
08/27/2003EP1014952B1 Multiple unit effervescent dosage form
08/27/2003EP0988057B1 Bioreductive conjugates for drug targeting
08/27/2003EP0936905B1 Immediate wettability water soluble film or water soluble layer for oral application
08/27/2003EP0930936B2 Method for preparing microcapsules of active substances coated with a polymer and novel microcapsules in particular resulting from the method
08/27/2003EP0914126B1 Sustained release sufentanil compositions
08/27/2003EP0909277B1 Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
08/27/2003EP0906089B1 Buccal delivery system
08/27/2003EP0806206B1 Aqueous compositions containing ciprofloxacine, and related use and process
08/27/2003EP0758237B1 Lactone stable formulation of camptothecin or 7-ethyl camptothecin in dimethylisosorbide or dimethylacetamide
08/27/2003EP0702793B1 Anti-cd3 antibody-aminodextran conjugates for induction of t-cell activation and proliferation
08/27/2003CN1439023A Amphiphilic macrocyclic derivatives and their analogues
08/27/2003CN1439021A Parathyroid hormone and parathyroid hormone-related protein receptor modulators
08/27/2003CN1438898A Aseptics
08/27/2003CN1438892A Low carbony drate compositions, kits thereof, and methods of use
08/27/2003CN1438889A Sustained-release preparations of quinolone antibiotics and method for prepartion thereof
08/27/2003CN1438888A 稳定的液体制剂 Stable liquid formulation
08/27/2003CN1438887A 水性液体制剂 The aqueous liquid preparation
08/27/2003CN1438882A Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
08/27/2003CN1438881A The Controlled release preparation of insulin and its method
08/27/2003CN1438880A Method for preparing a composition
08/27/2003CN1438879A Endoparasiticidal composition for voluntary oral ingestion by animals
08/27/2003CN1438878A Topical pharmaceutical formulations and methods of treatment
08/27/2003CN1438877A Prolonged release micro spheres for injection delivery and preparation method
08/27/2003CN1438876A Wet milling process
08/27/2003CN1438875A Method for making particles for use in a pharmaceutical composition
08/27/2003CN1438874A Powder compositions
08/27/2003CN1438861A Minimizing adverse experience associated with oxybutynin therapy
08/27/2003CN1438858A Biodegradable vehicles and delivery systems of biologically active substances
08/27/2003CN1438037A Supersonic contrast medium and supersonic contrast medium simultaneously as medicine and gene target carrier
08/27/2003CN1438036A Medical carrier gel ointment
08/27/2003CN1119173C Methods for preparing gas-filled liposomes
08/27/2003CN1119172C Chitosan/gelatin network modification on surface of aliphatic polyester
08/27/2003CN1119146C Compositions and kits for increasing the oral bioavailability of pharmaceutical agents
08/27/2003CN1119080C Implantable agarose-collagen beads containing cells which produce a diffusible bilogical product, and uses thereof
08/26/2003US6610869 Branched, substantially unsaturated ester oils
08/26/2003US6610868 Conjugated linoleic acid compositions and methods of making same
08/26/2003US6610825 Method for alleviating pain or providing an analgesic effect in a patient
08/26/2003US6610764 Polyhydroxyalkanoate compositions having controlled degradation rates
08/26/2003US6610740 A nutritional, cosmetic or pharmaceutical formulation comprising esters of polyethylene glycol
08/26/2003US6610735 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide)
08/26/2003US6610670 Cyclodextrin-drospirenone inclusion complexes
08/26/2003US6610669 Preparing water insoluble biocompatible gel by reacting polyanionic polysaccharide with activating agent in aqueous solution containing water miscible organic solvent selected from lower alkanols and polar aprotic solvents
08/26/2003US6610668 Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
08/26/2003US6610667 Compositions for treatment of disorders of the oesophagus
08/26/2003US6610661 Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
08/26/2003US6610651 Molecules that home to various selected organs or tissues
08/26/2003US6610624 Method for enhancing catalytic activity with supercritical fluids
08/26/2003US6610348 Gelling agents and gels containing them
08/26/2003US6610329 Compositions for the delivery of antigens
08/26/2003US6610327 Oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals.
08/26/2003US6610325 Pharmaceutical medicine comprises an iron salt, not less than two polyols, a binding agent, a lubricating agent, and a flavoring agent. The dose of elemental iron is not less than 5 mg, and preferably 10 mg to 15 mg per tablet. The polyols are
08/26/2003US6610322 Liposome suspension forms spontaneously upon adding a diacylglycerol-PEG lipid to an aqueous solution when the lipid has appropriate packing parameters and the adding occurs above the melting temperature of the lipid. Combinations of lipids
08/26/2003US6610321 Emulsion formulations for hydrophilic active agents
08/26/2003US6610320 Mixture of cocoa plant extract and antichloesterol agent
08/26/2003US6610318 Sterile ophthalmological gel preparation applicable in drops and process for producing it
08/26/2003US6610310 Immunology response; side effect reduction
08/26/2003US6610309 Vaccines; mixture of antigen and water solubility organometallic compound
1 ... 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 ... 1712